Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Sacubitril 24 mg + Valsartan 26 mg tablet
Therapeutic Category
Hypertension/ Blood Pressure, Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10x14
Price
₹365/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Sacustep 50 Tablet is a prescription medication that combines Sacubitril and Valsartan in a fixed-dose formulation. This combination belongs to a class of drugs known as angiotensin receptor neprilysin inhibitors (ARNIs). Sacubitril is a neprilysin inhibitor that helps increase the levels of beneficial peptides like natriuretic peptides, which promote vasodilation and reduce blood pressure. Valsartan, an angiotensin II receptor blocker (ARB), works by blocking the effects of angiotensin II, a hormone that causes blood vessels to constrict, thereby lowering blood pressure and reducing strain on the heart. Together, they provide a synergistic effect that helps in improving heart function and reducing the risk of cardiovascular events, particularly in patients with chronic heart failure with reduced ejection fraction (HFrEF). Sacustep 50 is formulated to provide effective blood pressure control, reduce hospitalizations, and improve survival in patients suffering from heart failure. It represents a modern and evidence-based approach to the long-term management of heart failure and is typically used as a replacement for ACE inhibitors or ARBs in patients who tolerate it.
Some commonly reported side effects of Sacustep 50 Tablet include dizziness, low blood pressure (hypotension), increased potassium levels (hyperkalemia), fatigue, and kidney function impairment. Cough may occur in some cases. A rare but serious side effect is angioedema—swelling of the lips, face, or throat—which requires immediate medical attention. Regular monitoring of blood pressure, kidney function, and electrolyte levels is essential during treatment.
Sacustep 50 Tablet is primarily indicated for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in adult patients. It is prescribed to reduce the risk of cardiovascular death and heart failure-related hospitalizations. The medication is especially beneficial in patients who remain symptomatic despite optimal standard treatment with ACE inhibitors, ARBs, beta-blockers, and diuretics.
Sacustep 50 Tablet should only be used under medical supervision. It must not be used together with ACE inhibitors due to the risk of serious side effects such as angioedema. There should be a washout period of at least 36 hours if switching from an ACE inhibitor. This medication is not recommended during pregnancy or while breastfeeding. Patients with a history of angioedema or severe liver impairment should not take this medication. Always inform your doctor about any other medications or health conditions before starting treatment with Sacustep 50. Regular follow-up and laboratory tests are essential for safe and effective use.
Store Sacustep 50 Tablet in a cool and dry place below 30°C. Keep it away from moisture, direct sunlight, and heat. Ensure the medication is stored out of reach of children and pets. Do not use the tablet past its expiry date. Keep the product in its original packaging until use to protect it from light and humidity.
Composition : Amlodipine 10 mg Tablet
Composition : Amlodipine 2.5 mg Tablet
Composition : Amlodipine 5 mg Tablet
Composition : Amlodipine 5mg + Atenolol 50mg Tablet
Composition : Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet
Composition : Atenolol 50 MG Tablet
Composition : Azelnidipine 16 Tablet
Composition : Benidipine 4mg + Telmisartan 40mg Tablet
Composition : Bisoprolol 1.25 MG Tablet
Composition : Bisoprolol 2.5 MG Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Sacubitril 24 mg + Valsartan 26 mg Tablet is an advanced cardiovascular combination therapy used for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). The combination works by improving heart function, reducing cardiovascular stress, and lowering the risk of hospitalization and cardiovascular death. It is widely prescribed by cardiologists and cardiac care specialists, making it a premium product in the cardiovascular and chronic care segment with strong growth potential in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from the growing demand for modern heart failure management therapies. Sacubitril + Valsartan is commonly prescribed as a long-term treatment, ensuring regular repeat prescriptions, stable sales volumes, and continuous demand from cardiology clinics, hospitals, and retail pharmacies.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiovascular and cardiac care segment, including Sacubitril 24 mg + Valsartan 26 mg Tablet. We provide monopoly rights, quality-assured manufacturing, promotional support, and reliable product supply to help franchise partners establish a strong presence in the cardiac care market.
Wholesalers and stockists benefit from strong prescription-based demand, increasing adoption among cardiologists, and long-term patient usage. Since heart failure requires continuous management and follow-up therapy, this product offers steady product movement, recurring business opportunities, and sustainable profitability in pharmaceutical distribution.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and heart failure management products can contact Cafoli Lifecare to discuss pricing, product availability, monopoly franchise rights, and PCD pharma franchise opportunities. We provide complete support through marketing materials, dependable supply chains, and territory-based business assistance to help partners grow their pharmaceutical business successfully.